Coming up

| Updated on January 12, 2018


Expectations and blips in 2017

It’s 2017 and the medical devices industry starts off with discussions with the Centre on cardiac stents — the latter is keen to control the prices of these devices. The pharma industry expects to take a marginal WPI-linked price increase on medicines in the NLEM in the coming months. The industry projects growth this fiscal to close at 11 per cent, and FY18, at 12 per cent. A handful of Indian companies still have to resolve their issues with the USFDA. Clinical trials, combination drugs and drug price control litigation are scheduled for hearings at various courts and their outcomes will have vast impact.

Published on January 06, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor